London, 9 September 2019, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, on communications activities surrounding its recent £100 million oversubscribed Series B financing.
Achilles is a biopharmaceutical company leading the next wave of immune-oncology drug development using T cell therapies to target neoantigens in non-small cell lung cancer and melanoma. The company’s pioneering technology allows individualised treatments to potentially target and destroy tumours without harming healthy tissue. Proceeds from this financing will enable the delivery of two human proof-of-concept studies using a personalised T cell therapy approach in non-small cell lung cancer and melanoma, expected to enter the clinic this year. Additionally, the financing will help progress the solid-tumour pre-clinical product pipeline as well as increasing the company’s manufacturing capabilities.
“We are delighted to have advised Achilles on their financial and strategic communications in this highly successful series B fundraising. Achilles’ pioneering approach to tackling cancer is moving rapidly into the clinic and we are excited to continue to work closely with the company as it executes on its strategy.”
Sukaina Virji
Senior Associate Partner at Consilium Strategic Communications
To view Achilles’ announcement please visit: https://achillestx.com/.